(3.238.82.77)
[ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2016, Volume : 9, Issue : 11
First page : ( 2041) Last page : ( 2042)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2016.00417.0

Prednisolone in alcoholic liver disorder

Thaminee S.

Saveetha Dental College and Hospital, Poonamallee High Road, Chennai-600 077

Corresponding Author E-mail:

Online published on 2 March, 2017.

Abstract

Aim and Objective

Alcohol is leading cause for liver disease and is associated with morbidity and mortality. Several factors including the amount and duration of alcohol consumption affect the development and progression of alcoholic disorder. Alcoholic hepatitis is a devastating acute form of alcoholic liver disease (ADL). Prednisone for alcoholic liver disease is an effective medication and it improves short term survival in patients.

Background

Alcoholic hepatitis is a clinical syndrome characterised by jaundice and liver impairment that occurs in patients with a history of heavy and prolonged alcohol consumption. The short-term mortality among patients with severe disease exceeds 30%. Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists. Result: Prednisolone was associated with a reduction in 28-day mortality that did not reach significance and with no improvement in outcomes at 90 days or 1 year. Prednisolone Reduced mortality, improved risk-benefit. Treatment with Prednisolone improves the short term survival of patients with severe biopsy proved alcoholic hepatitis.

Top

Keywords

Alcoholism, Alcoholic Hepatitis, Alcoholic Liver Disease, Prednisolone.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
816,841,097 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.